AbbVie (NYSE:ABBV) Issues Q1 2026 Earnings Guidance

AbbVie (NYSE:ABBV) updated its first quarter 2026 earnings guidance on Wednesday. The company provided EPS guidance of 2.970-3.010 for the period, compared to the consensus EPS estimate of 3.110. The company issued revenue guidance of $14.7 billion-$14.7 billion, compared to the consensus revenue estimate of $15.0 billion. AbbVie also updated its FY 2026 guidance to 14.370-14.570 EPS.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on ABBV. Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. Morgan Stanley raised their price objective on shares of AbbVie from $261.00 to $269.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. UBS Group reissued a “neutral” rating on shares of AbbVie in a report on Tuesday, January 13th. JPMorgan Chase & Co. increased their price target on AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research report on Monday, November 3rd. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $258.00 price objective on shares of AbbVie in a research report on Thursday, January 15th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $251.50.

AbbVie Trading Down 3.8%

Shares of NYSE:ABBV traded down $8.62 during trading on Wednesday, hitting $217.04. 15,291,947 shares of the company’s stock were exchanged, compared to its average volume of 7,605,424. The firm has a market cap of $383.59 billion, a P/E ratio of 164.42, a PEG ratio of 0.93 and a beta of 0.35. The firm has a 50-day moving average price of $223.99 and a two-hundred day moving average price of $219.14. AbbVie has a 1-year low of $164.39 and a 1-year high of $244.81.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. During the same period in the previous year, the firm earned $2.16 earnings per share. The firm’s quarterly revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, research analysts predict that AbbVie will post 12.31 EPS for the current year.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q4 beat and raised guidance — AbbVie reported adjusted Q4 EPS of $2.71 and revenue of $16.62B (both above consensus) and guided FY‑2026 adjusted EPS to $14.37–$14.57, underpinning near‑term earnings visibility. AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results
• Positive Sentiment: Immunology momentum — Skyrizi and Rinvoq drove double‑digit growth in the immunology portfolio and helped lift overall revenue ~10% YoY; management says newer immunology sales helped beat expectations. AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs
• Positive Sentiment: Pipeline expansion — AbbVie filed regulatory applications for Rinvoq (upadacitinib) in vitiligo, which would expand indications and provide additional growth optionality if approved. AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®)
• Neutral Sentiment: Analyst positioning mixed but not uniformly negative — some firms (Evercore/others) maintain bullish views citing immunology momentum and neurology upside, supporting longer‑term conviction. AbbVie Buy Thesis Anchored by Robust Immunology Momentum, Neurology Upside, and Long-Term IBD Defense
• Neutral Sentiment: Some commentators view the selloff as a buying opportunity given fundamentals and dividend/institional support, so technical buyers may step in at these levels. MarketBeat AbbVie coverage
• Negative Sentiment: Aesthetics and filler weakness — Allergan/Aesthetics (Botox/Juvederm) showed softer results and investor focus on “filler” weakness pressured the stock despite the companywide beat. AbbVie stock slides as investors focus on aesthetics weakness
• Negative Sentiment: Diversification concerns and a downgrade — some analysts question growth durability outside immunology as oncology and aesthetics declined, and one downgrade highlighted reliance on M&A and the exclusion of IPR&D/milestone costs from guidance. AbbVie’s Immunology Fortress Can’t Hide Cracks In Diversification (Downgrade)
• Negative Sentiment: Profit‑taking despite beat — commentary notes that Rinvoq and some oncology lines missed investor expectations and management excluded acquired IPR&D/milestone impacts from guidance, keeping uncertainty around 2026 cash/earnings assumptions. This helped trigger the selloff. AbbVie Beats on Q4 Earnings, Stock Down Despite Upbeat ’26 View

Institutional Investors Weigh In On AbbVie

Large investors have recently made changes to their positions in the stock. Quarry LP bought a new stake in AbbVie during the 3rd quarter worth $41,000. Rakuten Securities Inc. boosted its stake in shares of AbbVie by 26.5% during the second quarter. Rakuten Securities Inc. now owns 368 shares of the company’s stock valued at $68,000 after purchasing an additional 77 shares in the last quarter. Binnacle Investments Inc boosted its stake in shares of AbbVie by 33.2% during the second quarter. Binnacle Investments Inc now owns 493 shares of the company’s stock valued at $92,000 after purchasing an additional 123 shares in the last quarter. Triumph Capital Management bought a new stake in shares of AbbVie during the third quarter worth about $193,000. Finally, Turning Point Benefit Group Inc. acquired a new position in shares of AbbVie in the third quarter valued at approximately $213,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.